3Leucht S, Leucht S, Leucht S, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials [J]. Am J Psychiatry, 2003, 160(7): 1209-1222.
4Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis [J]. Am J Psychiatry, 1999, 156(I 1): 1686-1696.
5Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder [J]. Am J Psychiatr)5 2004, 161 (10): 1837-1847.
6Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine [J]. Int Clin Psychopharmacol, 200S, 20(2): 10S-112.
7Breier A, Berg PH, "Ihakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia [J]. Am J Psychiatr: 2005,162( 10): 1879-1887.
8Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia [J]. AmJ Psychiatry, 2005, 162(8): 1535-1538.
9Grootens KP, Van Veelen NM, Peuskens J, et al. Ziprasidone vs Olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial [J]. Schizophr Bull, 2011, 37(2): 352-361.
10Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia [J]. Cochrane Database Syst Rev, 2010(3): CD006654.
